ATRX Immunohistochemistry Antibody

ATRX (Immunohistochemistry) Antibody

Reliable Detection of ATRX Protein Expression and Nuclear Loss in Gliomas

The ATRX antibody, developed by Talent Biomedical, is a high-affinity immunohistochemical reagent designed to detect the expression and loss of the ATRX protein in human tissue samples.
The ATRX gene (Alpha Thalassemia/Mental Retardation Syndrome X-linked) encodes a chromatin remodeling factor that plays an essential role in DNA replication, transcriptional regulation, and nucleosome stability.

Loss of ATRX expression has been strongly correlated with IDH1-mutant astrocytomas and serves as a powerful molecular biomarker for the diagnosis and subclassification of diffuse gliomas.
In IHC analysis, ATRX displays a distinct nuclear brown staining pattern in normal cells, while absence of nuclear staining within tumor cells indicates mutation or deletion of the ATRX gene.

🌐 Fardad Azma Rad Co.

Fardad Azma Rad Co., the exclusive distributor of Talent Biomedical Technology Co., Ltd. (China) in Iran, supplies a full range of professional immunohistochemistry (IHC) antibodies including ATRX.
With a strong focus on diagnostic accuracy, global manufacturing standards, and technical expertise, Fardad Azma Rad provides advanced solutions to pathology and molecular diagnostic laboratories nationwide.

🔬 Key Advantages

• Highly specific nuclear biomarker for identifying IDH1-mutant astrocytomas

• Reliable tool for assessing ATRX loss in gliomas and glioblastomas

• Produces clear, consistent nuclear staining with excellent sensitivity

• Optimized for FFPE samples and compatible with DAB detection systems

• Stable for up to 18 months under refrigerated conditions (2–8 °C)

💡 Diagnostic Use

• Molecular diagnosis and grading of Astrocytomas and Glioblastomas

• Differentiation between Oligodendroglioma and Astrocytoma

• Research on ATRX and IDH1 mutations in glial tumors

• Determination of tumor prognosis and therapeutic response

“Download Brochure”